ClinicalTrials.gg
CompletedNCT03437447Updated Sep 18, 2019Results posted

Praziquantel Bioequivalence Study

A Phase 1 interventional study of Cisticid and Biltricide in Healthy, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in Mexico. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-09-18.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 1, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The purpose of this trial is to assess the bioequivalence (BE) of new 600 milligram (mg) Cisticid tablet (Test) versus 600 mg Biltricide tablets (Reference) at a dose of 1200 mg in healthy male participants. Praziquantel (PZQ) is the active ingredient for Cisticid and Biltricide tablets.

02

Conditions studied

  • Healthy

Keywords

  • Bioavailability
  • Bioequivalence
  • Praziquantel
  • Cysticide
  • Pharmacokinetics
03

In context

Lead sponsor

Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A male participant must agree to use and to have their female partners willing to use additional non-hormonal (for example, condoms or occlusive cap with spermicide, non-hormonal intra-uterine device [IUD], previous sterilization of participant or his partner, being sexually inactive) from Day of randomization up to final end of treatment (EOT) visit
  • Gave written prior to any trial related procedure
  • Have a body weight (BW) of greater than (>) 55.0 kilogram (kg) to less than (\<) 95 kg and a (BMI) between 18.0 and 27.0 kg/meter square (m\^2)
  • Able to communicate well with the Investigator, understanding the protocol requirements and restrictions, and willing to comply with the requirements of the entire trial
  • Non-smoker (= 0 cigarettes, pipes, cigars or others) since at least three months
  • recording (12-lead) without signs of pathology in particular heart-rate corrected [] (Bazett) \<450 milliseconds (ms)
  • Vital signs should be in normal range (systolic blood pressure: 90 to 140 millimeters of mercury [mmHg]; diastolic blood pressure: 50 to 90 mmHg; pulse rate: 45 to 90 beats per minute [bpm]; oral body temperature between 35.0 degree centigrade [°C] to 37.5°C)
  • All values for biochemistry, liver function test and hematology tests of blood and urine within the normal range or showing no clinically relevant deviation as judged by the Investigator. Hematocrit and must be above the lower limit; upper limit may range up to 15 percent (%). Remaining results, including white blood cells may range +/- 15%, if participant is asymptomatic
  • Negative screen for alcohol and drugs of abuse (opiate class, barbiturates, cocaine and metabolites, amphetamines, cannabinoids, benzodiazepines and tricyclic antidepressants) at screening and on each admission
  • Negative screen for surface (HBs) antigens, Virus (HCV) antibodies, Hepatitis A Virus (HAV) antibodies and (HIV) 1 and 2 antibodies
  • Other protocol defined inclusion criteria could apply

Exclusion criteria

Exclusion Criteria:

  • Any surgical or medical condition, including findings in the medical history or in the pre-study assessments, or any other significant disease, that in the opinion of the Investigator, constitutes a risk or a for the participation of the participant in the study or that could interfere with the study objectives, conduct or evaluation
  • History of surgery of the gastrointestinal (GI) tract, history of other GI tract diseases, or acute GI tract infections in the last 2 weeks, which could influence the gastrointestinal absorption and/or motility according to the Investigator's opinion
  • Any abnormality in the safety laboratory parameters as judged by the Investigator
  • Have positive results from serology examination for surface (HBs) antigen, Virus (HCV) or (HIV)
  • Allergy: ascertained or presumptive to the active drug substance and/or formulations' ingredients; history of anaphylaxis to drugs or allergic reactions in general, which the Investigator considers may affect the outcome of the trial
  • History or presence of drug abuse (opiate class, barbiturates, cocaine and its main metabolite, amphetamines, cannabinoids, benzodiazepines and tricyclic antidepressants) or alcohol abuse at screening and on each admission. Alcohol abuse is defined by the assessment of the Investigator
  • Loss or donation of more than 400 milliliter (mL) of blood within 90 days prior to first Praziquantel (PZQ) administration
  • Administration of any product or use of any investigational device in any clinical study within 30 days prior to first PZQ administration. Participants who have used drugs that may affect the pharmacokinetics of PZQ from 14 days before dosing until the last pharmacokinetic (PK) sample, for example, phenytoin, barbiturates, primidone, carbamazapine, oxcarbazepine, topiramate, felbamate, rifampicin, nelfinavir, ritonavir, griseofulvin, oral ketoconazole
  • Consumption of substances known to be potent inhibitors or inducers of Cytochrome P450s (CYP P450s) such as grapefruit, orange, cranberry or juices of these fruits, herbal remedies or dietary supplements containing St. John's Wort, poppy seeds, cruciferic vegetables, in the two weeks before dosing until last PK sample
  • Unlikely to comply with the protocol requirements, instructions and trial-related restrictions, for example, uncooperative attitude, inability to return for follow-up visits, and improbability of completing the trial
  • Non-acceptance or non-compliance with the study breakfast (for example, vegetarians, vegans and participants who follow special diets)
  • Excessive consumption of beverages containing xanthine (>5 cups of coffee a day or equivalent) or inability to stop consuming caffeine from 48 hours prior to drug administration until discharge from the clinic
  • Participant is the Investigator or any Sub-Investigator, research assistant, pharmacist, trial coordinator, other staff or relative thereof directly involved in the conduct of the trial
  • Vulnerable participants (for example, persons kept in detention)
  • Legal incapacity or limited legal capacity
  • Other protocol defined exclusion criteria could apply
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    First Cisticid, Then Biltricide, Then Biltricide

    Cisticid (Test) in Treatment Period 1 followed by Biltricide (Reference) in Treatment Period 2 and Treatment Period 3. A washout period of 7 days will be maintained between 3 treatment periods.

    Drug: Cisticid · Drug: Biltricide

  • Experimental
    First Biltricide, Then Cisticid, Then Biltricide

    Biltricide (Reference) in Treatment Period 1 followed by Cisticid (Test) in Treatment Period 2 and then Biltricide (Reference) in Treatment Period 3. A washout period of 7 days will be maintained between 3 treatment periods.

    Drug: Cisticid · Drug: Biltricide

  • Experimental
    First Biltricide, Then Biltricide, Then Cisticid

    Biltricide (Reference) in Treatment Period 1 and Treatment Period 2 followed by Cisticid (Test) in Treatment Period 3. A washout period of 7 days will be maintained between 3 treatment periods.

    Drug: Cisticid · Drug: Biltricide

Interventions

  • DrugPraziquantelStudies of PraziquantelPraziquantel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants received single oral dose of 1200 mg (two 600 mg tablets) Cisticid (Test) on Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2) or Day 15 (Treatment Period 3).

    Also known as: Praziquantel

  • DrugPraziquantelStudies of PraziquantelPraziquantel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants received 600 mg of Biltricide (Reference) tablet at a dose of 1200 mg on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).

    Also known as: Praziquantel

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of L-Praziquantel (L-PZQ)

    Area under the plasma concentration-time curve from 0 to the time of the last quantifiable concentration.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose

  2. Maximum Observed Plasma Concentration (Cmax) of L-Praziquantel (L-PZQ)

    The maximum observed plasma concentration of L-Praziquantel (L-PZQ).

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose

Secondary outcomes

  1. Time to Reach Maximum Plasma Concentration (Tmax) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)

    Time of the maximum drug concentration.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose

  2. Time Prior to the First Measurable (Non-zero) Concentration (Tlag) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)

    Time prior to the first measurable (non-zero) concentration; calculated as last time point at which the concentration is less than (\<) Lower Limit of Quantification (LLOQ) before the occurrence of the first quantifiable concentration.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose

  3. Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)

    AUC0-inf is defined as the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose

  4. Extrapolated Area Under the Plasma Concentration Curve From Time Tlast to Infinity (AUCextra) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)

    AUCextra was reported in terms of percentage of AUC0-inf.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose

  5. Terminal Elimination Half-Life (t1/2) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)

    Elimination Half Life (t1/2) was defined as the time required for the concentration or amount of drug in the body to be reduced by one-half.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose

  6. Terminal Elimination Rate Constant (Lambda Z) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)

    Lambda Z was determined from the terminal slope of the log-transformed plasma concentration curve using linear regression method.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose

  7. Apparent Clearance (CL/f) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose

  8. Apparent Volume of Distribution During Terminal Phase (Vd/f) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)

    Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vd/f after oral dose was influenced by the fraction absorbed.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose

  9. Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Racemate PZQ (Rac-PZQ)

    Area under the drug plasma concentration-time curve from time zero to the time last measurable concentration.

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose

  10. Maximum Observed Plasma Concentration (Cmax) of Racemate PZQ (Rac-PZQ)

    The maximum observed plasma concentration of rac-Praziquantel (rac-PZQ).

    Time frame: Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose

  11. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs

    An adverse event (AE) was defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug. TEAEs included both Serious TEAEs and non-serious TEAEs.

    Time frame: Baseline up to Day 29

  12. Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters

    Number of participants with clinically significant abnormalities in laboratory parameters were reported. Laboratory investigation included hematology, biochemistry, urinalysis and coagulation.

    Time frame: Baseline up to Day 29

  13. Number of Participants With Clinically Significant Abnormalities in Vital Signs

    Number of participants with clinically significant abnormalities in vital signs were reported. Vital signs included body temperature, systolic / diastolic blood pressure, and pulse rate.

    Time frame: Baseline up to Day 29

  14. Number of Participants With Clinically Significant Abnormalities in 12-lead Electrocardiogram (ECG) Findings

    Number of participants with clinically significant abnormalities in 12-lead electrocardiogram (ECG) were reported. The 12-lead ECGs were recorded after the participants have rested for at least 5 minutes in supine position.

    Time frame: Baseline up to Day 29

07

Results

Posted Sep 18, 2019

Participant flow

Treatment Period 1
Participant flow — Treatment Period 1
MilestoneFirst Cisticid, Then Biltricide, Then BiltricideFirst Biltricide, Then Cisticid, Then BiltricideFirst Biltricide, Then Biltricide, Then Cisticid
Started202020
Completed202019
Not completed001
Withdrew: Withdrawal by subject001
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneFirst Cisticid, Then Biltricide, Then BiltricideFirst Biltricide, Then Cisticid, Then BiltricideFirst Biltricide, Then Biltricide, Then Cisticid
Started202019
Completed202019
Not completed000
Treatment Period 3
Participant flow — Treatment Period 3
MilestoneFirst Cisticid, Then Biltricide, Then BiltricideFirst Biltricide, Then Cisticid, Then BiltricideFirst Biltricide, Then Biltricide, Then Cisticid
Started202019
Completed202019
Not completed000

Outcome measures

PrimaryArea Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of L-Praziquantel (L-PZQ)

Area under the plasma concentration-time curve from 0 to the time of the last quantifiable concentration.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose
Reported as:
Mean · Hour*nanogram per milliliter (h*ng/ml)
Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of L-Praziquantel (L-PZQ)
Hour*nanogram per milliliter (h*ng/ml)CisticidBiltricide First AdministrationBiltricide Second Administration
Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of L-Praziquantel (L-PZQ)441.53 ± 345.70547.41 ± 384.82460.25 ± 343.37
PrimaryMaximum Observed Plasma Concentration (Cmax) of L-Praziquantel (L-PZQ)

The maximum observed plasma concentration of L-Praziquantel (L-PZQ).

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of L-Praziquantel (L-PZQ)
ng/mLCisticidBiltricide First AdministrationBiltricide Second Administration
Maximum Observed Plasma Concentration (Cmax) of L-Praziquantel (L-PZQ)310.87 ± 249.02426.42 ± 324.01363.20 ± 333.50
SecondaryTime to Reach Maximum Plasma Concentration (Tmax) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)

Time of the maximum drug concentration.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose
Reported as:
Median · hours
Time to Reach Maximum Plasma Concentration (Tmax) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)
hoursCisticidBiltricide First AdministrationBiltricide Second Administration
L-PZQ2.5 (1.5 to 5.5)2 (1 to 3.5)2.5 (1 to 4.5)
Rac-PZQ2.5 (1.5 to 5.5)2 (1 to 3.5)2.5 (1 to 4.5)
SecondaryTime Prior to the First Measurable (Non-zero) Concentration (Tlag) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)

Time prior to the first measurable (non-zero) concentration; calculated as last time point at which the concentration is less than (\<) Lower Limit of Quantification (LLOQ) before the occurrence of the first quantifiable concentration.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose
Reported as:
Median · hours
Time Prior to the First Measurable (Non-zero) Concentration (Tlag) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)
hoursCisticidBiltricide First AdministrationBiltricide Second Administration
L-PZQ1 (0.25 to 3)1 (0.25 to 2.5)1 (0.25 to 3.5)
Rac-PZQ0.75 (0.00 to 2.00)0.75 (0.25 to 2.00)0.75 (0 to 2.5)
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)

AUC0-inf is defined as the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-inf).

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose
Reported as:
Mean · h*ng/ml
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)
h*ng/mlCisticidBiltricide First AdministrationBiltricide Second Administration
L-PZQ468.52 ± 352.29584.23 ± 410.05497.89 ± 348.81
Rac-PZQ2130.19 ± 1417.812509.42 ± 1624.332189.25 ± 1403.14
SecondaryExtrapolated Area Under the Plasma Concentration Curve From Time Tlast to Infinity (AUCextra) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)

AUCextra was reported in terms of percentage of AUC0-inf.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose
Reported as:
Mean · Percentage of AUC0-inf
Extrapolated Area Under the Plasma Concentration Curve From Time Tlast to Infinity (AUCextra) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)
Percentage of AUC0-infCisticidBiltricide First AdministrationBiltricide Second Administration
L-PZQ5.36 ± 3.735.49 ± 6.475.74 ± 4.02
Rac-PZQ2.60 ± 1.732.84 ± 2.562.57 ± 1.56
SecondaryTerminal Elimination Half-Life (t1/2) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)

Elimination Half Life (t1/2) was defined as the time required for the concentration or amount of drug in the body to be reduced by one-half.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose
Reported as:
Mean · hours
Terminal Elimination Half-Life (t1/2) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)
hoursCisticidBiltricide First AdministrationBiltricide Second Administration
L-PZQ1.87 ± 1.122.59 ± 3.012.32 ± 1.65
Rac-PZQ2.19 ± 0.912.54 ± 1.732.18 ± 0.90
SecondaryTerminal Elimination Rate Constant (Lambda Z) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)

Lambda Z was determined from the terminal slope of the log-transformed plasma concentration curve using linear regression method.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose
Reported as:
Median · Per hour
Terminal Elimination Rate Constant (Lambda Z) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)
Per hourCisticidBiltricide First AdministrationBiltricide Second Administration
L-PZQ0.452927 (0.103378 to 1.120808)0.383267 (0.032567 to 0.721124)0.370854 (0.073375 to 0.944209)
Rac-PZQ0.365639 (0.135661 to 0.646499)0.331359 (0.060282 to 0.635357)0.370806 (0.125134 to 0.638226)
SecondaryApparent Clearance (CL/f) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose
Reported as:
Mean · Milliliter per hour
Apparent Clearance (CL/f) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)
Milliliter per hourCisticidBiltricide First AdministrationBiltricide Second Administration
L-PZQ749261.50 ± 744206.88585260.42 ± 541013.95673193.51 ± 531848.19
Rac-PZQ147268.6 ± 122977.13128110.14 ± 122864.03155851.99 ± 145104.37
SecondaryApparent Volume of Distribution During Terminal Phase (Vd/f) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vd/f after oral dose was influenced by the fraction absorbed.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose
Reported as:
Mean · Milliliter
Apparent Volume of Distribution During Terminal Phase (Vd/f) of L-Praziquantel (L-PZQ) and Racemate PZQ (Rac-PZQ)
MilliliterCisticidBiltricide First AdministrationBiltricide Second Administration
L-PZQ1540237.10 ± 1069504.211660474.33 ± 1619772.261800582.47 ± 1385707.17
Rac-PZQ430368.23 ± 328721.73385223.26 ± 279076.69431494.33 ± 350782.53
SecondaryArea Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Racemate PZQ (Rac-PZQ)

Area under the drug plasma concentration-time curve from time zero to the time last measurable concentration.

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose
Reported as:
Mean · h*ng/ml
Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Racemate PZQ (Rac-PZQ)
h*ng/mlCisticidBiltricide First AdministrationBiltricide Second Administration
Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Racemate PZQ (Rac-PZQ)2071.35 ± 1370.582421.73 ± 1518.942131.01 ± 1353.64
SecondaryMaximum Observed Plasma Concentration (Cmax) of Racemate PZQ (Rac-PZQ)

The maximum observed plasma concentration of rac-Praziquantel (rac-PZQ).

Time frame:
Pre-dose, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 8.0, 9.0, 10.0 and 12.0 hours post-dose
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Racemate PZQ (Rac-PZQ)
ng/mLCisticidBiltricide First AdministrationBiltricide Second Administration
Maximum Observed Plasma Concentration (Cmax) of Racemate PZQ (Rac-PZQ)1209.15 ± 803.201530.23 ± 944.121356.18 ± 1011.46
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs

An adverse event (AE) was defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug. TEAEs included both Serious TEAEs and non-serious TEAEs.

Time frame:
Baseline up to Day 29
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs
ParticipantsCisticidBiltricide First AdministrationBiltricide Second Administration
Participants with TEAEs256
Participants with Serious TEAEs000
SecondaryNumber of Participants With Clinically Significant Abnormalities in Laboratory Parameters

Number of participants with clinically significant abnormalities in laboratory parameters were reported. Laboratory investigation included hematology, biochemistry, urinalysis and coagulation.

Time frame:
Baseline up to Day 29
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters
ParticipantsCisticidBiltricide First AdministrationBiltricide Second Administration
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters000
SecondaryNumber of Participants With Clinically Significant Abnormalities in Vital Signs

Number of participants with clinically significant abnormalities in vital signs were reported. Vital signs included body temperature, systolic / diastolic blood pressure, and pulse rate.

Time frame:
Baseline up to Day 29
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Vital Signs
ParticipantsCisticidBiltricide First AdministrationBiltricide Second Administration
Number of Participants With Clinically Significant Abnormalities in Vital Signs000
SecondaryNumber of Participants With Clinically Significant Abnormalities in 12-lead Electrocardiogram (ECG) Findings

Number of participants with clinically significant abnormalities in 12-lead electrocardiogram (ECG) were reported. The 12-lead ECGs were recorded after the participants have rested for at least 5 minutes in supine position.

Time frame:
Baseline up to Day 29
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in 12-lead Electrocardiogram (ECG) Findings
ParticipantsCisticidBiltricide First AdministrationBiltricide Second Administration
Number of Participants With Clinically Significant Abnormalities in 12-lead Electrocardiogram (ECG) Findings000

Adverse events

Collected over Baseline up to Day 29. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cisticid0/60 (0%)0/60 (0%)2/60 (3.3%)
Biltricide First Administration0/60 (0%)0/60 (0%)5/60 (8.3%)
Biltricide Second Administration0/60 (0%)0/60 (0%)6/60 (10%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventCisticidBiltricide First AdministrationBiltricide Second Administration
NauseaGastrointestinal disorders0/600/602/60
AnaemiaBlood and lymphatic system disorders0/602/600/60
Joint injuryInjury, poisoning and procedural complications1/600/600/60
HeadacheNervous system disorders1/600/601/60
CoughRespiratory, thoracic and mediastinal disorders0/600/601/60
Aspartate Aminotransferase IncreasedInvestigations0/600/601/60
Alanine Transaminase IncreasedInvestigations0/600/601/60
Multiple injuriesInjury, poisoning and procedural complications0/600/601/60
Head injuryInjury, poisoning and procedural complications0/601/600/60
Abdominal painGastrointestinal disorders0/601/600/60

Baseline characteristics

All participants who were randomized into the study.

Age, Continuous
Age, Continuous(Years)First Cisticid, Then Biltricide, Then BiltricideFirst Biltricide, Then Cisticid, Then BiltricideFirst Biltricide, Then Biltricide, Then CisticidTotal
Mean27.80 ± 7.8328.65 ± 7.4627.20 ± 5.3127.88 ± 6.86
Sex: Female, Male
Sex: Female, Male(Participants)First Cisticid, Then Biltricide, Then BiltricideFirst Biltricide, Then Cisticid, Then BiltricideFirst Biltricide, Then Biltricide, Then CisticidTotal
Female0000
Male20202060
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)First Cisticid, Then Biltricide, Then BiltricideFirst Biltricide, Then Cisticid, Then BiltricideFirst Biltricide, Then Biltricide, Then CisticidTotal
Hispanic or Latino20202060
Not Hispanic or Latino0000
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)First Cisticid, Then Biltricide, Then BiltricideFirst Biltricide, Then Cisticid, Then BiltricideFirst Biltricide, Then Biltricide, Then CisticidTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race20202060
Unknown or Not Reported0000
08

Study locations

1 site
  • Clínica de Enfermedades Crónicas y de Procedimientos Especiales, Sociedad Civil (SC)
    México, 58249, Mexico
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2018 to primary completion in Jul 2018, 0 months.

Results were first posted in Sep 2019, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2018
First posted
Feb 19, 2018
StartActual
Jun 18, 2018
Primary completionActual
Jul 6, 2018
CompletionActual
Jul 6, 2018
Results first posted
Sep 18, 2019
Last update
Sep 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03437447
Responsible party
Sponsor
First posted
Feb 19, 2018
Start date
Jun 18, 2018
Primary completion
Jul 6, 2018
Completion
Jul 6, 2018
Results posted
Sep 18, 2019
Last update
Sep 18, 2019

Study contacts

Medical Responsible
study director · Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Praziquantel

Start the discussion